INmune Bio (NASDAQ: INMB), an immunology company focused on
developing treatments that harness the patient’s innate immune system to fight
disease, recently reported financial results for the second quarter ended June
30, 2019 (http://ibn.fm/shHin).
An article discussing the company reads, “Apart from announcing strategic
developments, INmune Bio also presented its most important financial results
for the second quarter. Net loss attributable to common stockholders for the
second quarter was $0.4 million, in comparison to $6.2 million for the same
quarter of 2018. Research and development expenditure remained unchanged at
$0.3 million. The total research and development expenditure was $0.6 million,
but it was partially offset by a $0.3 million Alzheimer’s Association grant. .
. . As of June 30, INmune Bio had cash and cash equivalents of $9.4 million
with no debt. In May 2019, INmune closed a private placement of nearly $4.7
million. As of August 9, INmune Bio has 10.8 million common and 13.9 million
fully diluted shares outstanding.”
To view the full article, visit http://ibn.fm/nUuwd
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB),
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product
platforms: two products that re-engineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that is currently
focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell
therapeutic that primes the patient’s NK cells to attack minimal residual
disease, the remaining cancer cells that are difficult to detect, which often
cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which
often cause resistance to immunotherapy, such as anti-PD-1 checkpoint
inhibitors. XPro1595 targets neuroinflammation, which causes microglial
activation and neuronal cell death. INmune Bio’s product platforms utilize a
precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment